Merck and Moderna have recently announced the initiation of a Phase 3 clinical trial to assess the efficacy of combining Merck’s renowned cancer drug, Keytruda, with V940 – an individualized neoantigen therapy that they are collaboratively developing. This study aims to investigate the potential benefits of this combination as an adjuvant treatment for patients diagnosed with certain types of resected non-small cell lung cancer.
Earlier, Merck and Moderna embarked on a Phase 3 study, evaluating the combination therapy in patients with resected high-risk melanoma with positive outcomes. Hence, they are now expanding their clinical development program to explore V940’s potential in treating additional tumor types.
Non-small cell lung cancer (NSCLC) poses a significant global health concern and is responsible for the majority (over 80%) of cancer-related deaths worldwide.
Keytruda, an immune system-activating cancer drug, empowers patients to combat tumors effectively. On the other hand, V940, an individualized neoantigen therapy, stimulates an antitumor immune response by generating specific T-cell reactions, tailored to each patient’s unique mutational signature.
These joint efforts from Merck and Moderna hold great promise in advancing cancer treatment strategies, bringing hope to patients affected by this devastating disease.